Chinese Journal of Organic Chemistry ›› 2022, Vol. 42 ›› Issue (7): 1974-1999.DOI: 10.6023/cjoc202202011 Previous Articles     Next Articles

REVIEWS

靶向新型冠状病毒SARS-CoV-2主蛋白酶的抗病毒药物研究进展

王春霞a,b, 胡晓东b, 许斌a,*(), 曹春阳b,*()   

  1. a上海大学理学院化学系 上海 200444
    b中国科学院上海有机化学研究所 生命有机化学国家重点实验室 上海 200032
  • 收稿日期:2022-02-16 修回日期:2022-04-06 发布日期:2022-08-09
  • 通讯作者: 许斌, 曹春阳
  • 基金资助:
    科技部重点研发项目(2017YFE0108200); 中国科学院战略性先导科技专项(XDB20000000); 国家自然科学基金(21977110); 国家自然科学基金(22177127); 国家自然科学基金(91753119); 及中国科学院分子合成卓越中心(FZHCZY020600)

Research Progress of Antiviral Drug Targeting the Main Protease of SARS-CoV-2

Chunxia Wanga,b, Xiaodong Hub, Bin Xua(), Chunyang Caob()   

  1. aDepartment of Chemistry, College of Science, Shanghai University, Shanghai 200444
    bState Key Lab of Bio-organic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032
  • Received:2022-02-16 Revised:2022-04-06 Published:2022-08-09
  • Contact: Bin Xu, Chunyang Cao
  • Supported by:
    National Key Research and Development Program of Ministry of Science and Technology(2017YFE0108200); Chinese Academy of Sciences Strategic Priority Research Program(XDB20000000); National Natural Science Foundation of China(21977110); National Natural Science Foundation of China(22177127); National Natural Science Foundation of China(91753119); Center for Excellence in Molecular Synthesis, Chinese Academy of Sciences(FZHCZY020600)

The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 in late 2019 posed a serious threat to the world population. Some effective vaccines are currently approved and widely used, but the long-term efficacy and safety of this intervention is controversial given the highly mutagenic nature of the coronavirus. In addition, some antiviral drugs show better effects, but their safety and universality have not been supported by more data. Coronavirus main protease (3CLpro) is a special cysteine protease in the coronavirus family, responsible for processing viral polyproteins to produce yield mature non-structural proteins, which play an important role in the life cycle of coronaviruses and are highly conserved, and therefor is considered as a prominent target for antiviral drug. Strucure studies provide valuable insight into the function of this protease and structural basis of rational inhibitor design. This paper reviews the structure of SARS-CoV-2 3CLpro and the research progress of bright spot inhibitors targeting 3CLpro so far, and introduces binding mode and the structure-activity relationships of inhibitors and 3CLpro in detail. Additionally, we broadly examine available antiviral activity, ADMET and animal tests of these inhibitors.

Key words: COVID-19, SARS-CoV-2, 3CLpro inhibitor, antivirals drug discovery